Second lethal events associated with treatment for Hodgkin's disease: a review of 2980 patients treated in a single Mexican institute

Leukemia & Lymphoma
A AvilésS Cleto

Abstract

Presence of second neoplasms and cardiac toxicity has been recognized as potential late lethal second events in patients treated for Hodgkin's disease. However, most reports analyze these association independently. We reviewed 2980 cases of patients treated during 1970-1995 with long-term follow-up (> 4 years) in an attempt to identify all late events in Hodgkin's disease secondary to the treatment or those which are unrelated. Three hundred and ten patients died, and of these 156 were secondary to relapse and tumor progression. Death associated second tumors and cardiac events were increased 37 fold and 29 fold respectively compared to the general population. The risk factors for this complications did not differ to previous reports and included alkylating agents and/or radiotherapy for second neoplasms and anthracycline therapy and radiotherapy for cardiac toxicity. Moreover, 61 patients died secondary to non-related events. Nevertheless, at 20-years overall survival was 90 % (95 % confidence interval (CI): 78 % to 97 %) and event free survival was 88 % (95 % CI: 76 % to 96 %) for these patients. Thus, second events, fatal in most cases, should be considered as an expected risk to the treatment in patients with Hodgkin's dise...Continue Reading

References

Jul 18, 1992·BMJ : British Medical Journal·P Carde
Jul 1, 1991·International Journal of Radiation Oncology, Biology, Physics·J M CossetM Hayat
Mar 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G CiminoD Giannarelli
Jan 4, 1990·The New England Journal of Medicine·J M KaldorD Assouline
Jan 1, 1986·Medical and Pediatric Oncology·K M Rowland, A Murthy
May 17, 1995·Journal of the National Cancer Institute·J F BoivinP Mauch
Apr 30, 1994·International Journal of Radiation Oncology, Biology, Physics·G BitiV Boddi
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S L HancockR T Hoppe
Feb 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J F AbrahamsenH Høst
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A HirschJ Yahalom
Mar 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M B LundK Forfang
Nov 22, 1997·International Journal of Radiation Oncology, Biology, Physics·L S ConstineA Muhs
May 14, 1998·British Journal of Cancer·J D BrierleyM Pintilie
Oct 27, 1998·International Journal of Radiation Oncology, Biology, Physics·P NyandotoH Joensuu
Nov 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M M HudsonW M Crist

❮ Previous
Next ❯

Citations

Jun 21, 2005·The Journal of Laboratory and Clinical Medicine·Giorgina SpecchiaArcangelo Liso
Sep 4, 2003·Leukemia & Lymphoma·Agustin AvilésMartha González
Oct 3, 2007·Hematology/oncology Clinics of North America·Berthe M P Aleman, Flora E van Leeuwen
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Berthe M P AlemanFlora E van Leeuwen
Dec 13, 2005·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·P TrippG Y Yang
Nov 9, 2017·American Journal of Hematology·Ana C XavierLuciano J Costa
Oct 20, 2005·The Cochrane Database of Systematic Reviews·J G FranklinL Specht
Nov 23, 2006·Blood·Berthe M P AlemanFlora E van Leeuwen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.